{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:39:53Z","timestamp":1794886793090,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell therapy is constrained by on-target, off-tumor toxicities and cellular exhaustion because of chronic antigen exposure. CARs incorporating small-molecule controlled on- and off-switches can enhance both safety and therapeutic efficacy but their design is limited by the scarcity of nonimmunogenic protein elements responsive to nonimmunosuppressive, clinically approved drugs with favorable pharmacodynamics. Here we combine rational design and library-based optimization of a protein\u2013protein interaction (PPI) of human origin to develop venetoclax-controlled drug-regulated off-switch PPI (DROP)-CARs. DROP-CARs enable dose-dependent release of the tumor-targeting scFv and consequent reduction in T cell binding to the tumor cell. Additionally, we present proof of concept for a dual DROP-CAR controlled by different small molecules, as well as for logic-gated synthetic receptors enabling STAT3 signaling. We demonstrate in vitro and in vivo function of DROP-CAR T cells and conclude that the approach holds promise for clinical application.<\/jats:p>","DOI":"10.1038\/s41589-026-02152-x","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T10:02:43Z","timestamp":1771495363000},"page":"1654-1665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug-controlled CAR T cells through the regulation of cell\u2013cell interactions"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-4015","authenticated-orcid":false,"given":"Leo","family":"Scheller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta Maria Paola","family":"Giordano Attianese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-4172","authenticated-orcid":false,"given":"Roc\u00edo","family":"Castellanos-Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0976-5395","authenticated-orcid":false,"given":"Rapha\u00ebl B.","family":"Di Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Barden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6408-7366","authenticated-orcid":false,"given":"Melanie","family":"Triboulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Hafezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailan","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cribioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Reichenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-0408","authenticated-orcid":false,"given":"Anthony","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-4508","authenticated-orcid":false,"given":"Sandrine","family":"Georgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benita","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-3240","authenticated-orcid":false,"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9177-0857","authenticated-orcid":false,"given":"Sai","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7377-8636","authenticated-orcid":false,"given":"Bruno E.","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-7194","authenticated-orcid":false,"given":"Melita","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2152_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2152_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2152_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49\u201362 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2152_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.copbio.2020.01.009","volume":"65","author":"E Lanitis","year":"2020","unstructured":"Lanitis, E., Coukos, G. & Irving, M. All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. Curr. Opin. Biotechnol. 65, 75\u201387 (2020).","journal-title":"Curr. Opin. Biotechnol."},{"key":"2152_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/imr.13252","volume":"320","author":"GMP Giordano-Attianese","year":"2023","unstructured":"Giordano-Attianese, G. M. P., Ash, S. & Irvine, M. Coengineering specificity, safety, and function into T cells for cancer immunotherapy. Immunol. Rev. 320, 166\u2013198 (2023).","journal-title":"Immunol. Rev."},{"key":"2152_CR6","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).","journal-title":"Science"},{"key":"2152_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40264-018-0779-3","volume":"42","author":"B Wolf","year":"2019","unstructured":"Wolf, B. et al. Safety and tolerability of adoptive cell therapy in cancer. Drug Saf. 42, 315\u2013334 (2019).","journal-title":"Drug Saf."},{"key":"2152_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101070","volume":"14","author":"E Moghanloo","year":"2021","unstructured":"Moghanloo, E. et al. Remote controlling of CAR-T cells and toxicity management: molecular switches and next generation CARs. Transl. Oncol. 14, 101070 (2021).","journal-title":"Transl. Oncol."},{"key":"2152_CR9","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 75, 3505\u20133518 (2015).","journal-title":"Cancer Res."},{"key":"2152_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14749-3","volume":"7","author":"S Park","year":"2017","unstructured":"Park, S. et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci. Rep. 7, 14366 (2017).","journal-title":"Sci. Rep."},{"key":"2152_CR11","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","volume":"25","author":"S Arcangeli","year":"2017","unstructured":"Arcangeli, S. et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol. Ther. 25, 1933\u20131945 (2017).","journal-title":"Mol. Ther."},{"key":"2152_CR12","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1016\/j.ymthe.2020.08.003","volume":"28","author":"RB Di Roberto","year":"2020","unstructured":"Di Roberto, R. B. et al. A functional screening strategy for engineering chimeric antigen receptors with reduced on-target, off-tumor activation. Mol. Ther. 28, 2564\u20132576 (2020).","journal-title":"Mol. Ther."},{"key":"2152_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2152_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077 (2015).","journal-title":"Science"},{"key":"2152_CR15","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh, L. et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185, 1745\u20131763 (2022).","journal-title":"Cell"},{"key":"2152_CR16","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","volume":"40","author":"HS Li","year":"2022","unstructured":"Li, H. S. et al. High-performance multiplex drug-gated CAR circuits. Cancer Cell 40, 1294\u20131305 (2022).","journal-title":"Cancer Cell"},{"key":"2152_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","volume":"13","author":"M Jan","year":"2021","unstructured":"Jan, M. et al. Reversible on- and off-switch chimeric antigen receptors controlled by lenalidomide. Sci. Transl. Med. 13, eabb6295 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2152_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.chembiol.2020.11.012","volume":"28","author":"S Carbonneau","year":"2021","unstructured":"Carbonneau, S. et al. An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell Chem. Biol. 28, 802\u2013812 (2021).","journal-title":"Cell Chem. Biol."},{"key":"2152_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20671-6","volume":"12","author":"S Park","year":"2021","unstructured":"Park, S. et al. Direct control of CAR T cells through small molecule-regulated antibodies. Nat. Commun. 12, 710 (2021).","journal-title":"Nat. Commun."},{"key":"2152_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nchembio.2529","volume":"14","author":"ZB Hill","year":"2018","unstructured":"Hill, Z. B., Martinko, A. J., Nguyen, D. P. & Wells, J. A. Human antibody-based chemically induced dimerizers for cell therapeutic applications. Nat. Chem. Biol. 14, 112\u2013117 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"2152_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nri2546","volume":"9","author":"A Thomson","year":"2009","unstructured":"Thomson, A., Turnquist, H. & Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9, 324\u2013337 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2152_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36","volume":"2","author":"V Kotla","year":"2009","unstructured":"Kotla, V. et al. Mechanism of action of lenalidomide in hematological malignancies. J. Hematol. Oncol. 2, 36 (2009).","journal-title":"J. Hematol. Oncol."},{"key":"2152_CR23","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","volume":"32","author":"H Ludwig","year":"2018","unstructured":"Ludwig, H. et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 32, 1542\u20131560 (2018).","journal-title":"Leukemia"},{"key":"2152_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41587-019-0403-9","volume":"38","author":"G Giordano-Attianese","year":"2020","unstructured":"Giordano-Attianese, G. et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nat. Biotechnol. 38, 426\u2013432 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2152_CR25","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.3390\/ijms19123950","volume":"19","author":"M Garc\u00eda-Aranda","year":"2018","unstructured":"Garc\u00eda-Aranda, M., P\u00e9rez-Ruiz, E. & Redondo, M. BCL-2 inhibition to overcome resistance to chemo- and immunotherapy. Int. J. Mol. Sci. 19, 3950 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2152_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25735-9","volume":"12","author":"S Shui","year":"2021","unstructured":"Shui, S. et al. A rational blueprint for the design of chemically-controlled protein switches. Nat. Commun. 12, 5754 (2021).","journal-title":"Nat. Commun."},{"key":"2152_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1023\/A:1006308826967","volume":"18","author":"MC Gong","year":"1999","unstructured":"Gong, M. C., Chang, S. S., Sadelain, M., Bander, N. H. & Heston, W. D. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 18, 483\u2013490 (1999).","journal-title":"Cancer Metastasis Rev."},{"key":"2152_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks, E. D. Venetoclax: first global approval. Drugs 76, 979\u2013987 (2016).","journal-title":"Drugs"},{"key":"2152_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting Bcl2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2152_CR30","doi-asserted-by":"publisher","first-page":"e010208","DOI":"10.1136\/jitc-2024-010208","volume":"12","author":"M Barden","year":"2024","unstructured":"Barden, M. et al. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. J. Immunother. Cancer 12, e010208 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2152_CR31","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2020-140907","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong, C. et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood 136, 1632\u20131644 (2020).","journal-title":"Blood"},{"key":"2152_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","volume":"211","author":"M Bachmann","year":"2019","unstructured":"Bachmann, M. The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells. Immunol Lett 211, 13\u201322 (2019).","journal-title":"Immunol Lett"},{"key":"2152_CR33","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438 (2018).","journal-title":"Cell"},{"key":"2152_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689\u2013702 (2009).","journal-title":"J. Immunother."},{"key":"2152_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"2152_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04744-1","volume":"9","author":"D Bojar","year":"2018","unstructured":"Bojar, D., Scheller, L., Hamri, G. C.-E., Xie, M. & Fussenegger, M. Caffeine-inducible gene switches controlling experimental diabetes. Nat. Commun. 9, 2318 (2018).","journal-title":"Nat. Commun."},{"key":"2152_CR37","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41589-018-0046-z","volume":"14","author":"L Scheller","year":"2018","unstructured":"Scheller, L., Strittmatter, T., Fuchs, D., Bojar, D. & Fussenegger, M. Generalized extracellular molecule sensor platform for programming cellular behavior. Nat. Chem. Biol. 14, 723\u2013729 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"2152_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature23271","volume":"548","author":"AA Green","year":"2017","unstructured":"Green, A. A. et al. Complex cellular logic computation using ribocomputing devices. Nature 548, 117\u2013121 (2017).","journal-title":"Nature"},{"key":"2152_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2326-6066.CIR-14-0192","volume":"3","author":"SP Santoro","year":"2014","unstructured":"Santoro, S. P. et al. T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol. Res. 3, 68\u201384 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2152_CR40","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1089\/hum.2021.173","volume":"32","author":"M Irving","year":"2021","unstructured":"Irving, M., Lanitis, E., Migliorini, D., Ivics, Z. & Guedan, S. Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells. Hum. Gene Ther. 32, 1044\u20131058 (2021).","journal-title":"Hum. Gene Ther."},{"key":"2152_CR41","doi-asserted-by":"publisher","first-page":"e20230903","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C. & Chen, Y. Y. CAR-T cell manufacturing: major process parameters and next-generation strategies. J. Exp. Med. 221, e20230903 (2024).","journal-title":"J. Exp. Med."},{"key":"2152_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405085121","volume":"121","author":"GMP Giordano Attianese","year":"2024","unstructured":"Giordano Attianese, G. M. P. et al. Dual on\/off-switch chimeric antigen receptor controlled by two clinically approved drugs. Proc. Natl Acad. Sci. USA 121, e2405085121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2152_CR43","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.1038\/bcj.2016.61","volume":"6","author":"M Cartellieri","year":"2016","unstructured":"Cartellieri, M. et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 6, e458\u2013e458 (2016).","journal-title":"Blood Cancer J."},{"key":"2152_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41571-021-00479-z","volume":"18","author":"M Jan","year":"2021","unstructured":"Jan, M., Sperling, A. S. & Ebert, B. L. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat. Rev. Clin. Oncol. 18, 401\u2013417 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2152_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber, E. W. et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 3, 711\u2013717 (2019).","journal-title":"Blood Adv."},{"key":"2152_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.864","volume":"3","author":"Y Nouri","year":"2023","unstructured":"Nouri, Y., Weinkove, R. & Perret, R. An in vitro model to assess CRS potential of CAR T cells using a tumor cell line and autologous monocytes. Curr. Protoc. 3, e864 (2023).","journal-title":"Curr. Protoc."},{"key":"2152_CR47","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl. Med. 13, eabe7378 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2152_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21078-7","volume":"12","author":"JH Cho","year":"2021","unstructured":"Cho, J. H. et al. Engineering advanced logic and distributed computing in human CAR immune cells. Nat. Commun. 12, 792 (2021).","journal-title":"Nat. Commun."},{"key":"2152_CR49","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41589-021-00926-z","volume":"18","author":"J Manhas","year":"2022","unstructured":"Manhas, J., Edelstein, H. I., Leonard, J. N. & Morsut, L. The evolution of synthetic receptor systems. Nat. Chem. Biol. 18, 244\u2013255 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"2152_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","volume":"33","author":"M Bachiller","year":"2025","unstructured":"Bachiller, M. et al. ARI0003: co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma. Mol. Ther. 33, 317\u2013335 (2025).","journal-title":"Mol. Ther."},{"key":"2152_CR51","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","volume":"53","author":"W Li","year":"2020","unstructured":"Li, W. et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity 53, 456\u2013470 (2020).","journal-title":"Immunity"},{"key":"2152_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.omtm.2021.03.007","volume":"21","author":"JY Ho","year":"2021","unstructured":"Ho, J. Y. et al. Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. Mol. Ther. Methods Clin. Dev. 21, 237\u2013246 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2152_CR53","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"2152_CR54","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","volume":"19","author":"M Mirdita","year":"2022","unstructured":"Mirdita, M. et al. ColabFold: making protein folding accessible to all. Nat. Methods 19, 679\u2013682 (2022).","journal-title":"Nat. Methods"},{"key":"2152_CR55","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1021\/acschembio.3c00012","volume":"18","author":"A Marchand","year":"2023","unstructured":"Marchand, A. et al. Rational design of chemically controlled antibodies and protein therapeutics. ACS Chem. Biol. 18, 1259\u20131265 (2023).","journal-title":"ACS Chem. Biol."},{"key":"2152_CR56","doi-asserted-by":"publisher","first-page":"e005091","DOI":"10.1136\/jitc-2022-005091","volume":"10","author":"N Camviel","year":"2022","unstructured":"Camviel, N. et al. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. J. Immunother. Cancer 10, e005091 (2022).","journal-title":"J. Immunother. Cancer"}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02152-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02152-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02152-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:22:16Z","timestamp":1790248936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02152-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2152"],"URL":"https:\/\/doi.org\/10.1038\/s41589-026-02152-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.06.606454","asserted-by":"object"}]},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T.R. holds shares of Alloy Therapeutics and Engimmune Therapeutics. S.T.R. is on the scientific advisory board of Alloy Therapeutics and Engimmune Therapeutics. M.I., B.E.C., G.G.A., L.S., and colleagues have provisional intellectual property rights for the DROP mechanism.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}